American pharmaceutical company Eli Lilly and Company has acquired biotechnology company Merida Biosciences, Inc. in a deal valued at up to $2.875 billion. The acquisition was announced on August 31, 2026, and completed in October 2026.
The main objective of this acquisition is to strengthen Eli Lilly’s immunology and autoimmune disease treatment pipeline.
Merida Biosciences was developing biological therapies designed to selectively eliminate harmful antibodies responsible for certain diseases. Its leading drug candidate, MER511, was being developed for Graves’ disease and Thyroid Eye Disease.
Key Acquisition Details
| Deal Detail | Information |
| Acquiring Company | Eli Lilly and Company |
| Acquired Company | Merida Biosciences, Inc. |
| Deal Type | Acquisition |
| Announcement Date | August 31, 2026 |
| Completion | October 2026 |
| Maximum Deal Value | Up to $2.875 billion |
| Payment Method | Cash |
| Payment Structure | Upfront + milestone payments |
| Acquirer Exchange | NYSE |
| Acquirer Ticker | LLY |
| Target Company | Privately held before acquisition |
| Acquisition Status | Completed |
Company Introduction:
Eli Lilly and Company
Headquarters: Indianapolis, Indiana, USA
NYSE: LLY
What Does Eli Lilly Do?
The company develops medicines across several major healthcare areas:
- Diabetes: Medicines for blood sugar management.
- Obesity: Treatments for weight management.
- Oncology: Cancer treatments.
- Immunology: Treatments for immune system-related diseases.
- Neuroscience: Medicines for brain and nervous system disorders.
Mounjaro and Zepbound are among its well-known medicines.
Why Did Eli Lilly Acquire Merida?
Eli Lilly wants to expand beyond its existing medicines into new treatment areas. Merida’s antibody-targeting technology offers Lilly an opportunity to develop new therapies for autoimmune and allergic diseases.
Merida Biosciences
United States | Biotechnology
What Does Merida Biosciences Do?
In some autoimmune diseases, the immune system mistakenly produces antibodies that attack the body’s own healthy tissues. These are known as pathogenic autoantibodies.
Merida was developing therapies designed to selectively eliminate these harmful antibodies while aiming to preserve normal immune system functions.
Its two major research programs were MER511 and MER769.
What Is the Main Objective of the Acquisition?
The main objective is to integrate Merida’s antibody-degradation technology into Eli Lilly’s research and drug development network.
The key strategic objectives include:
- Expanding Immunology: Developing new medicines for autoimmune diseases.
- Acquiring New Technology: Gaining a research platform that targets harmful antibodies.
- Strengthening the Drug Pipeline: Advancing drug candidates such as MER511 and MER769.
- Healthcare Innovation: Exploring new treatment options for Graves’ disease and allergic conditions.
- Long-Term Growth: Investigating the technology’s potential in other antibody-related diseases.
These are strategic objectives, not guarantees of successful drug development.
How Does Merida’s Technology Work?
Merida’s technology focuses on selectively targeting and degrading antibodies that contribute to certain diseases.
Normally, antibodies help the immune system fight viruses and bacteria. However, in autoimmune diseases, some antibodies mistakenly attack healthy organs and tissues.
Merida’s approach aims to eliminate these specific harmful antibodies rather than broadly suppressing the entire immune system.
Simple Example: Imagine a machine that has one defective component affecting its performance. Instead of shutting down the entire machine, removing only the defective component may allow the rest of the system to continue operating.
Merida’s technology follows a similar concept by targeting disease-causing antibodies.
This is an investigational approach, and its effectiveness must be established through clinical trials.
MER511: Drug Candidate for Graves’ Disease and Thyroid Eye Disease
MER511 was Merida’s leading drug candidate. It was being developed for two autoimmune conditions.
A. Graves’ Disease
Graves’ disease is an autoimmune condition in which the immune system produces antibodies that can overstimulate the thyroid gland. This can result in excessive thyroid hormone production.
Common symptoms include:
- Rapid heartbeat.
- Unexplained weight loss.
- Anxiety and nervousness.
- Hand tremors.
- Increased sensitivity to heat.
B. Thyroid Eye Disease (TED)
Thyroid Eye Disease is a condition in which immune system activity affects the tissues around the eyes. It can cause swelling, eye pain, double vision, and bulging eyes.
MER511 is designed to target harmful thyroid-stimulating antibodies associated with these conditions.
Early Clinical Results
According to Eli Lilly, early Phase 1 data for MER511 showed a substantial reduction in harmful antibodies and an encouraging initial safety profile.
However, these early findings do not establish that the drug can cure the diseases. Further clinical trials are required to evaluate its effectiveness and safety.
MER769: Research for Allergies and Asthma
MER769 was Merida’s second important research program. It focused on allergic diseases associated with an antibody called IgE.
Its main research areas included:
- Food Allergy: Allergic reactions triggered by certain foods.
- Asthma: Certain forms of asthma involving allergic immune responses.
- Chronic Spontaneous Urticaria: A condition involving recurring itchy skin rashes and hives without an obvious trigger.
MER769 was designed to target harmful antibody activity associated with allergic conditions.
At the time of the acquisition announcement, it was still in the preclinical research stage, meaning it had not yet progressed into clinical trials.
Other Merida Research Programs
Apart from MER511 and MER769, Merida’s research pipeline also included kidney-related and other immune-mediated diseases.
One important research area was Membranous Nephropathy, a kidney disease in which immune-related processes can damage the kidney’s filtering system.
| Drug / Program | Research Area | Stage at Announcement |
| MER511 | Graves’ disease and Thyroid Eye Disease | Phase 1 |
| MER769 | Food allergy and asthma | Preclinical |
| Other research | Membranous nephropathy and immune-related diseases | Early research |
These stages reflect the pipeline status at the time of the acquisition announcement, not an updated clinical status for November 2026.
$2.875 Billion Deal Value and Payment Structure
The maximum announced value of the acquisition is $2.875 billion. The transaction involves cash consideration with two major components.
1. Upfront Payment
An initial cash payment is made to Merida’s shareholders as part of the acquisition.
2. Milestone Payments
Additional payments may become payable in the future if specified clinical and regulatory milestones are achieved.
For example, if a drug candidate reaches a particular clinical or regulatory milestone defined in the agreement, an additional payment may become due.
Important: The $2.875 billion does not mean the entire amount was paid immediately. It represents the maximum potential consideration, including the upfront payment and future milestone payments. The public announcement did not disclose their individual amounts.
Why Did Eli Lilly Make This Acquisition?
A. Expansion Beyond Diabetes and Obesity
Eli Lilly has a strong presence in diabetes and obesity medicines. Acquiring Merida provides an opportunity to expand its research capabilities in immunology and autoimmune disease treatments.
B. Access to New Treatment Technology
Merida’s approach focuses on targeting specific disease-causing antibodies rather than broadly suppressing immune system activity.
C. Using Existing Research Capabilities
Lilly can potentially use its research, clinical development, and manufacturing resources to advance Merida’s drug candidates.
D. Future Business Opportunities
Merida’s technology could create research opportunities across several autoimmune and allergic conditions. However, each potential treatment will require separate clinical evidence.
What Happens to Merida After the Acquisition?
Following the completion of the acquisition in October 2026, Merida Biosciences became a wholly owned subsidiary of Eli Lilly.
This means:
- Merida is now owned by Eli Lilly.
- Its research platform is part of Lilly’s corporate group.
- Drug candidates such as MER511 and MER769 can be developed further.
- Merida’s research capabilities may benefit from Lilly’s resources.
Risks and Challenges of the Acquisition
Although the acquisition offers several opportunities, it also involves important risks.
- Clinical Trial Risk: Positive early Phase 1 data does not guarantee success in later trials.
- Regulatory Approval: New medicines must receive approval from regulatory authorities such as the FDA.
- Research Costs: Developing and testing biological medicines can be expensive.
- Commercial Success: Even promising technology must demonstrate clinical value and market acceptance.
- Milestone Payments: Lilly may have to make additional payments when specified milestones are achieved.
What Does Eli Lilly Gain from This Deal?
The acquisition provides Eli Lilly with three important assets:
- Antibody-Degradation Platform: Research technology designed to selectively eliminate harmful antibodies.
- MER511: A clinical-stage drug candidate for Graves’ disease and Thyroid Eye Disease.
- MER769: An early-stage research program targeting food allergies and asthma.
The acquisition expands Lilly’s immunology research pipeline and provides opportunities to explore new treatments for diseases that currently have unmet medical needs.
However, the actual financial and medical benefits will become clearer only after further clinical development and regulatory approvals.
Conclusion
Eli Lilly’s acquisition of Merida Biosciences, valued at up to $2.875 billion, is an important transaction in the pharmaceutical and biotechnology industry.
Through this deal, Lilly gained access to technology designed to target harmful antibodies associated with autoimmune and allergic diseases.
Merida’s MER511 drug candidate was being developed for Graves’ disease and Thyroid Eye Disease, while MER769 focused on allergies and asthma.
The acquisition was completed in October 2026, and Merida is now a wholly owned subsidiary of Eli Lilly.
Overall, this acquisition is part of Eli Lilly’s long-term strategy to expand its research capabilities in immunology and autoimmune disease treatments. Its ultimate success will depend on future clinical results and the development of successful medicines.
Official Sources
- Eli Lilly – Official Acquisition Announcement
- SEC – Eli Lilly Q3 2026 Filing
- Merida Biosciences – Official Website
Disclaimer: MER511 and MER769 are investigational drug candidates, not approved medicines. This article is for business and educational information only, not medical advice.
